FDA’s CDER Introduces New ARC Program to Accelerate Rare Disease Cures

The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) announced the launch of the Accelerating Rare disease Cures (ARC) Program.

The ARC Program is managed by CDER’s Rare Diseases Team.

The vision of the ARC program is to accelerate and increase the development of safe and effective treatment options to address the unmet medical needs of patients with rare diseases.